Published in final edited form as:

Atherosclerosis. 2010 May ; 210(1): 51–56. doi:10.1016/j.atherosclerosis.2009.10.027.

Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm

Jonathan Golledge, MChir¹, Bradford Cullen, PhD¹, Catherine Rush, PhD¹, Corey S. Moran, PhD¹, Emma Secomb, FRACS¹, Frances Wood¹, Alan Daugherty, DSc², Julie H. Campbell, PhD³, and Paul E. Norman, DS⁴

¹ The Vascular Biology Unit, School of Medicine, James Cook University, Townsville, QLD, Australia

² Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA

³ Centre for Research in Vascular Biology, University of Queensland, Brisbane, QLD, Australia

⁴ School of Surgery and Pathology, University of Western Australia, Fremantle Hospital, Fremantle, WA, Australia

Abstract

Objective—Osteopontin (OPN) is associated with human abdominal aortic aneurysms (AAA) and *in vitro* studies suggest that this cytokine is downregulated by peroxisome proliferator-activated receptor (PPAR) ligation. We examined the effect of two PPAR ligands within a mouse model of aortic aneurysm.

Methods—At 11 weeks of age apolipoprotein E deficient (ApoE^{−/−}) mice were given pioglitazone (n=27), fenofibrate (n=27) or vehicle (n=27) in their drinking water. From 13 weeks of age mice received angiotensin II (1μg/kg/min) infusion via subcutaneous pumps until death or 17 weeks when the aortas were harvested and maximum aortic diameters were recorded. Suprarenal aortic segments were assessed for OPN concentration and macrophage accumulation. Saline infused mice served as negative controls (n=22).

Results—Angiotensin II induced marked dilatation in the suprarenal aorta (>2-fold increase compared to controls) associated with upregulation of the cytokines OPN and macrophage infiltration. Suprarenal aortic expansion was significantly reduced by administration of pioglitazone (mean diameter 1.61±0.11mm, p=.011) and fenofibrate (mean diameter 1.51±0.13mm, p=.001) compared to the vehicle control group (mean diameter 2.10±0.14mm). Immunostaining for macrophages was reduced in mice treated with pioglitazone (median staining area 6.2%, interquartile range 4.1–7.2, p<.001) and fenofibrate (median staining area 4.0%, interquartile range 2.2–6.1, p<.001) compared to mice receiving vehicle control (median staining area 13.2%, interquartile range 8.4–20.0).

Conclusion—These findings suggest the potential value of peroxisome proliferator-activated receptor ligation as a therapy for human AAAs.

Correspondence to: Professor Jonathan Golledge, Director, The Vascular Biology Unit, Department of Surgery, School of Medicine, James Cook University Townsville, QLD, Australia 4811. Fax +61 7 4796 1401 Telephone +61 7 4796 1417, jonathan.golledge@jcu.edu.au.

Conflict of interest

None declared.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Aortic aneurysm; medication; treatment

Introduction

Abdominal aortic aneurysm (AAA) is a common cause of death in Western countries [1]. The widespread use of imaging and the introduction of ultrasound surveillance programs in some regions have been associated with large numbers of asymptomatic small AAAs being detected [2]. Early elective surgery of small AAAs has not been demonstrated to reduce mortality [3]. In order to identify potential therapies for small AAA a number of studies have been carried out in animal models but many of the medications found to date would require prolonged development and testing in order to establish safe prescription in patients [4,5]. Peroxisome proliferator-activated receptors (PPAR) are a group of nuclear receptors which can be activated by endogenous and drug ligands [6,7]. PPAR γ is ligated by the thiazolidinedione pioglitazone and PPAR α by the fibric acid derivative fenofibrate [6,7]. Both PPAR α and γ ligation have also been shown to reduce cytokine production and inflammation, including osteopontin (OPN) concentration, which we have previously linked with AAA [6–8]. In the present study we investigated the effect of pioglitazone and fenofibrate in slowing aortic dilatation in a mouse model of AAA.

Methods

Mice

This investigation conforms with the *Guide for the Care and Use of Laboratory Animals* published by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996). Ethical approval was obtained from the local institutional committee prior to commencement of the study. Male apolipoprotein E (ApoE^{−/−}) mice at 11 weeks of age (obtained from Animal Resources Centre, Canning Vale, Western Australia) received either vehicle control (0.1% carboxymethylcellulose), pioglitazone (50mg/kg/d) or fenofibrate (100mg/kg/d) in their drinking water. At 13 weeks of age mice were anaesthetised by intraperitoneal injection of ketamine (150mg/kg) and xylazine (10mg/kg). Osmotic minipumps (Model 2004, ALZET, Durect Corporation, Cupertino, California, USA) placed into the subcutaneous space along the dorsal midline delivered 1 μ g/kg/min of angiotensin II (Sigma-Aldrich, Castle Hill, Australia) dissolved in sterile saline over 28 days. Age-matched ApoE^{−/−} male mice (n=22) in which osmotic pumps delivered sterile saline (referred to as saline controls), served as controls. Mice were maintained on a normal laboratory diet. After the 28 day infusion (or death), mice were sacrificed by CO₂ asphyxiation, the aortas were perfused with PBS and harvested from arch to iliac bifurcation. Segments from the aortic arch (left atrium to left subclavian artery origin) were fixed for atheroma assessment. Segments from suprarenal aorta (diaphragm to the lowest renal artery) were divided transversely in half and stored at −20°C for later analysis by histology, immunohistochemistry (mounted in OCT embedding medium) and ELISA.

Aorta Morphometry

Aortas were placed on a black background and digitally photographed (Coolpix 4500, Nikon). Maximum diameter of the aortic arch, thoracic aorta, suprarenal aorta and infrarenal aorta was determined from the images using computer-aided analysis (Scion Image, Scion Corporation). We have previously established that these measurements could be repeated with good intra-observer reproducibility [9].

Suprarenal aortic OPN measurement

Protein was extracted from individual frozen suprarenal aortic segments by homogenising in buffer (10mM cacodylic acid, 60mM L-arginine, 0.25% triton x-100 in PBS, pH 7.2) and centrifuging at $18,000 \times g$ at 4°C for 20 mins. Supernatant protein was quantified by the Bradford technique (Protein Assay, Bio-Rad, Hercules, California, USA). OPN concentration was measured by ELISA (Quantikine, R&D Systems MOST00 for OPN) and expressed as pg/mg of protein. We have previously reported excellent reproducibility of similar assays [10]. All mice in which the aorta did not rupture had segments of suprarenal aorta examined for these cytokines.

Histology and immunohistochemistry

Suprarenal aortic segments from ten mice from each group were selected using a random number generator. Serial cryostat sections 7µM thick were cut from each segment and stained for OPN and macrophages. For each stain, all 40 sections were stained simultaneously, using identical reagents and incubation times. Serial frozen sections were air-dried, fixed in acetone for 10 mins at -20 °C, air dried and rehydrated with PBS before being incubated in 3% H₂O₂/0.1% sodium azide/PBS to block endogenous peroxidase. For OPN detection, slides were incubated in 2% normal goat serum (Vector Laboratories) in PBS and endogenous avidin and biotin blocked using Avidin/Biotin blocking kit (Vector Laboratories), then 2µg/ml rabbit anti-mouse OPN (clone O-17, Immuno Biological Laboratories), biotinylated goat anti-rabbit IgG (Vector Laboratories) and Vectastain Elite ABC-HRP. Rabbit IgG (Vector Laboratories) was used as isotype control antibody. For macrophage detection, sections were blocked in 2% normal goat serum in PBS followed by staining using pan-macrophage antibody (clone MOMA-2, Abcam), and goat anti-rat HRP (Chemicon). Rat IgG (Sigma) was used as isotype control. Slides were incubated in the peroxidase substrate 3,3'-diamminobenzidine (ImmPACT DAB, Vector), counterstained in Mayer's Haematoxylin, dehydrated, cleared in xylene and mounted in Depex mounting medium. Stained sections were photographed using a Leica BMLB microscope fitted with a SPOTTM CCD Camera (Diagnostic Instruments, Inc., USA) and digital images captured to a PC supported with SPOT32TM software (version 2.1.2.; Diagnostic Instruments, Inc., USA). Identical exposure times and settings were used for all sections. Image analysis was performed on digital tiff images using Adobe Photoshop CS3 Extended software. For each section, the total tissue area and area of macrophage staining were measured using the "Selection Tool" and "Record Measurements" functions. Macrophage staining was expressed as a percentage of total tissue area, i.e. area macrophage staining/total tissue area x100. Measurements were made by two independent readers and the reproducibility of results analysed using Pearsons' correlation coefficient, coefficient of variation and Bland-Altman plots. Correlation coefficient was 0.98 and mean coefficient of variation was $8.8 \pm 5.9\%$. Examples of staining including positive and negative controls are shown in supplementary figures 1 and 2. Sections of atheroma from elderly ApoE^{-/-} mice were used as positive controls.

Atheroma assessment

Aortic arches were analysed from only 12 of the mice infused with saline but for all the mice receiving angiotensin II and medication (vehicle control 27, pioglitazone 27, fenofibrate 27). After being photographed, aortic arch segments were fixed overnight in 10% neutrally buffered formalin, transferred to 70% ethanol and stained with Sudan IV (0.1% Sudan IV dissolved in equal parts acetone and 70% ethanol) in order to identify intimal atherosclerotic plaque, as previously described [11]. The arch was opened longitudinally, pinned out on sheets of white dental wax and digitally photographed (Coolpix 4500 Nikon camera, SMZ800 Nikon dissecting microscope). The amount of lesion formation was measured using computer-assisted analysis (Scion Image, Scion Corporation) and expressed as a percentage (Sudan IV stained area per total area of the aortic arch).

Statistical analysis

The primary aim of this study was to assess the effect of PPAR ligation by fenofibrate or pioglitazone on suprarenal aortic dilatation in angiotensin II infused ApoE^{-/-} mice. In order to assess this aim suprarenal aortic diameter after angiotensin II infusion was compared between mice receiving pioglitazone or fenofibrate with those receiving vehicle controls. As a secondary aim we also assess macrophage staining area and suprarenal aortic concentration of OPN. Finally as a measure of atherosclerosis we compared aortic arch Sudan IV staining areas. Since data was not normally distributed non-parametric tests were used. Maximal aortic diameters, macrophage staining area, OPN concentrations and Sudan IV staining area were compared between treatment and control groups using Mann-Whitney U test. The incidence of aortic rupture between treatment and control groups was compared by Fisher's exact test.

Results

Fenofibrate and pioglitazone reduce suprarenal aortic expansion

Angiotensin II infusion caused suprarenal aortic expansion and aortic rupture, as previously described (Table 1) [4,9]. Suprarenal aortic expansion was reduced in mice receiving fenofibrate ($p=0.001$ compared to vehicle control) or pioglitazone ($p=0.011$ compared to vehicle control) (Table 1). The relative reduction in mean suprarenal aortic diameter was 28 and 24% in mice treated with fenofibrate and pioglitazone, respectively (Table 1). The incidence of aortic rupture was not affected by either medication (Table 1).

Fenofibrate and pioglitazone reduce suprarenal aortic macrophage infiltration

Immunostaining area for macrophages within the suprarenal aorta was increased in mice receiving angiotensin II (median staining area 13.2%, interquartile range 8.4–20.0, $n=10$) compared to saline infused mice (median staining area 2.7%, interquartile range 2.5–3.9, $n=10$, $p<0.01$; Figs. 1 and 2). Mice receiving fenofibrate (median staining area 4.0%, interquartile range 2.2–6.1, $n=10$, $p<0.01$) or pioglitazone (median staining area 6.2%, interquartile range 4.1–7.2, $n=10$, $p<0.01$) had significantly smaller areas of macrophage staining in their suprarenal aortas compared to those treated with vehicle control (median staining area 13.2%, interquartile range 8.4–20.0, $n=10$).

Fenofibrate reduces suprarenal aortic concentration of OPN

Figure 3 illustrates the suprarenal aortic concentrations of OPN in relation to drug administration. Aortic OPN concentration was reduced in mice receiving fenofibrate (median in fenofibrate dosed mice 126pg/mg compared to vehicle control 3198pg/mg, $p=0.006$). Aortic OPN concentration was not significantly reduced in mice receiving pioglitazone (median in pioglitazone treated mice 1787pg/mg compared to vehicle control 3198pg/mg, $p=0.65$). Serial immunohistochemistry staining sections suggested that OPN was mainly distributed in areas of wall remodelling associated with macrophage accumulation, with reduction in staining for OPN in fenofibrate and pioglitazone treated mice (Fig. 4). The areas of atherosclerotic lesions in the aortic arch developing in these young mice was low (overall median area 1.26, interquartile range 0–4.02 %) and not altered by any drugs (Table 1 and Fig. 5).

Discussion

The main findings from this study are that the PPAR ligands fenofibrate and pioglitazone reduce aortic expansion induced by angiotensin II in young ApoE^{-/-} mice. These findings, together with a recent report that another PPAR γ ligand rosiglitazone reduces aortic expansion, suggest the potential value of PPAR ligands for treating AAAs [12]. The latter study also reported that rosiglitazone reduced the incidence of aortic rupture induced by angiotensin II in

12 months old ApoE^{-/-} mice. We found no effect of PPAR ligation on aortic rupture in the current study in which 3 month old mice were used.

The angiotensin II infused ApoE^{-/-} model is increasingly used in studies assessing the effect of pathways or medications in aortic aneurysm formation [1,4,5,9,10,12,13]. The model has some similarities to human AAA. Aneurysms are more common in male mice [14]; aortic dilatation is associated with inflammation and high concentrations of cytokines [9]; and aortic rupture occurs in larger aneurysms [4,12]. Some of the features of the model are, however, disparate from human AAAs, including the predilection to the suprarenal aorta and the involvement of dissection as an important feature of the pathology [15].

The relative reduction in mean suprarenal aortic diameters induced by fenofibrate and pioglitazone was 28 and 24% respectively. This degree of effect is comparable to that reported for other successful agents investigated in this and similar models including a chymase inhibitor (30%), a Rho-kinase inhibitor (28%), vitamin E (24%), 17 β -estradiol (23%) and simvastatin (17%) [4,16–19]. Matrix metalloproteinase inhibition using doxycycline has also been demonstrated to reduce aortic dilatation in this model, but maximum aortic diameter measurements were not reported [20]. The effect of rosiglitazone reported in 12 months old ApoE^{-/-} mice appears to be greater than the latter studies but was measured in a very different way using MRI, and mice with ruptured AAAs were excluded thus comparison is difficult [12]. In addition rosiglitazone reduced AAA formation and rupture when given one week after angiotensin II infusion was commenced. The latter is suggestive that PPAR γ ligation is able to inhibit AAA progression which we did not specifically investigate in this study.

Our findings suggest that PPAR ligands inhibit aortic expansion by reducing aortic inflammation. We found reduced infiltration of macrophages within the suprarenal aorta in mice treated with fenofibrate or pioglitazone. We also found lower concentrations of OPN within the aorta of mice treated with fenofibrate. OPN is a chemotactic cytokine for macrophages [21]. Circulating concentrations of OPN have been demonstrated to be increased in patients with AAA [8]. Mice deficient in OPN are resistant to angiotensin II induced AAA formation [22]. Thus the ability of fenofibrate to downregulate OPN is a plausible mechanism which may have contributed to reduce macrophage infiltration and suprarenal aortic dilatation in mice receiving this medication. OPN deficiency has also reported to reduce angiotensin II induced progression of atheroma in ApoE^{-/-} mice [22]. We did not find any reduction in aortic arch sudan IV staining area in mice receiving fenofibrate. We suspect that this disparity in effects of fenofibrate on aortic dilation and atheroma are related to the relatively small amount of intimal atherosclerosis in the young mice we used, as discussed further below. However it is possible there maybe mechanisms other than OPN reduction which are important in the beneficial effects of PPAR ligands such as downregulation of angiotensin type 1 receptors and osteoprotegerin [12,23].

Further support for the potential value of PPAR ligands in human AAA comes from previous studies demonstrating the ability of these medications to reduce inflammation and proteolysis in atherosclerosis [7,24]. Unlike some other medications, such as statins, PPAR ligands are not presently indicated in most patients with AAA making it more straightforward to investigate these drugs in a randomised clinical trial in patients. The dose of pioglitazone and fenofibrate used in this study is similar to previous rodent studies in which they have been shown to ligate PPAR γ and PPAR α , respectively [25,26]. They probably represent higher doses, based on the amount per weight, than currently used in patients where doses are in the range of 15–45 mg/day and 120 mg/day for pioglitazone and fenofibrate, respectively.

We also measured arch atheroma area in this study although this was not the primary aim of the work which was designed to look at AAA. Angiotensin II infusion has been reported to

promote intimal atheroma in 6 month old ApoE^{-/-} mice [13]. In the current study using 13 week old ApoE^{-/-} mice we found no promotion of aortic arch Sudan IV staining area. Previous studies in ApoE^{-/-} mice suggest the effects of angiotensin II are age and aortic region dependent [13,27,28]. Greater effects are seen within older mice and more distal aortic segments, such as the descending and abdominal aorta [13,27,28]. The current study was designed to look at AAA rather than atheroma thus the mice used were quite young and more distal aortic segments were saved for effects on AAA not atherosclerosis. The amount of arch atherosclerosis present was small and not affected by angiotensin II in line with a previous report, which suggests there is a time lag between aortic arch atherosclerosis progression and angiotensin II infusion in young mice of up to 14 weeks [27]. Experiments in older aged mice on high fat diets are likely to be more useful for studying the effects of these medications on atherosclerosis rather than AAA, as previously reported [29,30]. Use of aortic sinus, descending or abdominal aortic samples may have demonstrated effects of angiotensin II even in the younger mice used in this study however we were unable to carry out these studies. In conclusion, in this study we have demonstrated that the PPAR ligands fenofibrate and pioglitazone reduce aortic expansion in a mice model of AAA. These findings along with other recent studies suggest the potential value of these medications for treating human AAA.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Grants from the National Institute of Health, USA (RO1 HL080010-01) and NHMRC (project grant 379600) supported this work. JG and PEN are supported by Practitioner Fellowships from the NHMRC, Australia (431503 and 458505). ES was supported by a one year scholarship from The Royal Australasian College of Surgeons.

References

1. Golledge J, Muller J, Daugherty A, et al. Abdominal aortic aneurysm: pathogenesis and implications for management. *Arterioscler Thromb Vasc Biol* 2006;26:2605–2613. [PubMed: 16973970]
2. Fleming C, Whitlock EP, Beil TL, Lederle FA. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2005;142:203–11. [PubMed: 15684209]
3. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med* 2002;346:1437–1444. [PubMed: 12000813]
4. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, Feng Q, et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. *Circulation* 2005;111:2219–2226. [PubMed: 15851596]
5. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. *Nat Med* 2005;11:1330–1338. [PubMed: 16311603]
6. Nakamachi T, Nomiya T, Gizard F, Heywood EB, Jones KL, Zhao Y, Fuentes L, Takebayashi K, Aso Y, Staels B, Inukai T, Bruemmer D. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes. *Diabetes* 2007;56:1662–70. [PubMed: 17360982]
7. Pascual G, Fong AL, Ogawa S, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. *Nature* 2005;437:759–763. [PubMed: 16127449]
8. Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, et al. Association Between Osteopontin and Human Abdominal Aortic Aneurysm. *Arterioscler Thromb Vasc Biol* 2007;27:655–660. [PubMed: 17170369]

9. Rush C, Nyara M, Moxon JV, Trollope A, Cullen B, Golledge J. Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm. *BMC Genomics* 2009;10:298. [PubMed: 19580648]
10. Clancy P, Oliver L, Jayalath R, Buttner P, Golledge J. Assessment of a serum assay for quantification of abdominal aortic calcification. *Arterioscler Thromb Vasc Biol* 2006;26:2574–2576. [PubMed: 17053174]
11. van Royen N, Hoefer I, Böttinger M, Hua J, Grundmann S, Voskuil M, Bode C, Schaper W, Buschmann I, Piek JJ. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. *Circ Res* 2003;92:218–25. [PubMed: 12574150]
12. Jones A, Deb R, Torsney E, Howe F, Dunkley M, Gnaneswaran Y, Gaze D, Nasr H, Loftus IM, Thompson MM, Cockerill GW. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. *Circulation* 2009;119:3125–32. [PubMed: 19506106]
13. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. *J Clin Invest* 2000;105:1605–1612. [PubMed: 10841519]
14. Ailawadi G, Eliason JL, Roelofs KJ, Sinha I, Hannawa KK, Kaldjian EP, Lu G, Henke PK, Stanley JC, Weiss SJ, Thompson RW, Upchurch GR Jr. Gender differences in experimental aortic aneurysm formation. *Arterioscler Thromb Vasc Biol* 2004;24:2116–2122. [PubMed: 15331435]
15. Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol* 2003;23:1621–1626. [PubMed: 12855482]
16. Gavrila D, Li WG, McCormick ML, Thomas M, Daugherty A, Cassis LA, et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol* 2005;25:1671–1677. [PubMed: 15933246]
17. Martin-McNulty B, Tham DM, da Cunha V, Ho JJ, Wilson DW, Rutledge JC, et al. 17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol* 2003;23:1627–1632. [PubMed: 12855485]
18. Steinmetz EF, Buckley C, Shames ML, Ennis TL, Van Vickie-Chavez SJ, Mao D, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. *Ann Surg* 2005;241:92–101. [PubMed: 15621996]
19. Inoue N, Muramatsu M, Jin D, Takai S, Hayashi T, Katayama H, Kitaura Y, Tamai H, Miyazaki M. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. *Atherosclerosis* 2009;204:359–64. [PubMed: 18996524]
20. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol* 2003;23:483–488. [PubMed: 12615694]
21. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. *Cytokine Growth Factor Rev* 2008;19:333–45. [PubMed: 18952487]
22. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. *J Clin Invest* 2003;112:1318–31. [PubMed: 14597759]
23. Moran CS, Cullen B, Campbell JH, Golledge J. Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. *J Vasc Res* 2009;46:209–17. [PubMed: 18931513]
24. Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. *Circulation* 2003;108:2805–2811. [PubMed: 14610009]
25. Mohapatra J, Sharma M, Singh S, Chatterjee A, Swain P, Balaraman R, Patel PR, Jain MR. Subtherapeutic Dose of Pioglitazone Reduces Expression of Inflammatory Adipokines in db/db Mice. *Pharmacology* 2009;84:203–210. [PubMed: 19738399]

26. Xie W, Nie Y, Du L, Zhang Y, Cai G. Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. *Pharmacol Res* 2007;55:392–9. [PubMed: 17306985]
27. Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, Ichikawa I, Fazio S, Kon V. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. *Atherosclerosis* 2006;184:312–21. [PubMed: 16023123]
28. Zhou Y, Chen R, Catanzaro SE, Hu L, Dansky HM, Catanzaro DF. Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein-E-deficient mice. *Am J Hypertens* 2005;18:486–92. [PubMed: 15831357]
29. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fiévet C, Wright SD, Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. *J Biol Chem* 2002;277:48051–7. [PubMed: 12377786]
30. He L, Game BA, Nareika A, Garvey WT, Huang Y. Administration of pioglitazone in low-density lipoprotein receptor-deficient mice inhibits lesion progression and matrix metalloproteinase expression in advanced atherosclerotic plaques. *J Cardiovasc Pharmacol* 2006;48:212–222. [PubMed: 17110803]

Figure 1. Examples of macrophage staining in sections of suprarenal aorta from mice in relation to PPAR treatment

Examples of immunostaining for macrophages from 17 week old ApoE^{-/-} male mice that received a) a 4 week saline infusion, b) a 4 week angiotensin II infusion plus oral vehicle control, c) a 4 week angiotensin II infusion plus fenofibrate, d) a 4 week angiotensin II infusion plus pioglitazone.

Figure 2. Box plots showing staining area for macrophages in the suprarenal aorta of mice in relation to PPAR treatment

Ten harvested non-ruptured suprarenal aortic segments were randomly selected from each group for immunostaining for macrophages. Staining area was estimated by computer-aided analysis. Shown are box plots representing median and interquartile range of staining areas from mice for each group. Staining area for macrophages was reduced in mice receiving fenofibrate (* $p < 0.01$) or pioglitazone (** $p < 0.01$).

Figure 3. Suprarenal aortic OPN concentration in relation to PPAR agonists

Shown are box plots representing median and inter-quartile range of suprarenal aortic OPN for mice receiving different treatments. The 27 mice that ruptured their aorta and thus fresh aortic samples were unavailable were excluded from analysis. # The concentration of OPN was significantly reduced in mice receiving fenofibrate, $p=0.006$.

Figure 4. Examples of OPN in relation to macrophage staining in sections of suprarenal aorta from mice receiving vehicle control and fenofibrate
 OPN and macrophage staining were mainly distributed in the area of the remodelling aneurysm.

Figure 5.

Box plots showing the median and inter-quartile range of arch atheroma area in the mice in relation to drug treatment and angiotensin II infusion.

Table 1

Aortic diameters and ruptures in mice receiving different drugs.

Group	Saline infused control	Vehicle control	Fenofibrate	Pioglitazone
Number	22	27	27	27
Aortic rupture	0	9	12	6
Suprarenal (mm)	0.99 ± 0.08	2.10 ± 0.14	1.51 ± 0.13 [*]	1.61 ± 0.11 [*]
Aortic arch Sudan IV staining area (%) ^{**}	2.05 ± 0.75	2.24 ± 0.53	3.83 ± 0.80	2.42 ± 0.88

Shown are mean ± standard error of maximum diameters from the suprarenal aortic segments or staining area; and rupture numbers.

* p≤0.01 compared to vehicle control;

** Aortic arches were analysed from 12 mice in the saline control group and all other 81 mice.